- Home
- MANE vs ADNT Comparison
MANE vs ADNT Comparison
Compare MANE & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANE | ADNT |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MANE | ADNT |
|---|---|---|
| Price | $119.62 | $20.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $83.33 | $25.41 |
| AVG Volume (30 Days) | 685.3K | ★ 1.1M |
| Earning Date | 03-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $17,439,000,000.00 |
| Revenue This Year | N/A | $2.71 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | ★ N/A | $324.83 |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $36.26 | $17.68 |
| 52 Week High | $131.24 | $27.32 |
Technical Indicators
Market Signals| Indicator | MANE | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 47.98 |
| Support Level | $90.90 | $18.65 |
| Resistance Level | $131.24 | $23.72 |
| Average True Range (ATR) | 8.74 | 0.85 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 67.81 | 67.66 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.